CHRS - Earnings call transcript Q3 2024 | Coherus BioSciences, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day and thank you for standing by. Welcome to the Q3 2024 Coherus BioSciences Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Jodi Sievers, Head of Investor Relations. Please go ahead.

Jodi Sievers

Thank you, Daniel. to Third welcome Conference XXXX and Call. afternoon Coherus Quarter BioSciences Earnings Good

to are Officer. Officer; our Executive me Theresa Dias, discuss Joining today and Officer; results Commercial Dr. Coherus; Dr. McMichael, Chief Medical Chief Chief Officer Bryan Denny Chief Reider, Financial Development Paul LaVallee, Officer; Rosh of Chief Lanfear,

be the events. includes regarding to Coherus' to, current units Before we by to and expectations like labeling projections not CMO; that statements resume I'd following: about our the market include, remind and you and complete; packaging of are projections about CMO time will forward-looking will expenses. may future number about projections These the get started, that statements and but today's labeling and of completed packaging it that call number UDENYCA for take timing share additional the for expectations future and limited it packaging of revenues, about and timing that units our

issued these achievements All These of the or and are could performance results, forward-looking filed uncertainties are as substantial parties we those statements. and our by we guarantees performance cause our subject statements reliance are actual the control that press not well risks to beyond that our that implied uncertainties on forward-looking as our and differ documents future with and of from to are including and today risks involve manufacturing substantial uncertainties, that statements risks release third in the inherent process and SEC. discussed in

forward-looking now Denny. we undertake over call as made today I'll or and turn provided no revise date on the update statements Forward-looking call this are the duty statements. And to any to of

Dennis Lanfear

year, to to towards cancer extend afternoon, structure. make you, the operating updates joining execute advance thank Nine the X-part share growth, generation continue Today, innovative everyone, deliver from against pleased we're potential our us to to, today advancing Thank next months patient good for top third capital into to strategy the our improve progress on well we specifically XXXX. secondly, control survival with first, our therapies the call. drive quarter Good value; you Jodi. line and and and shareholder pipeline expenses, long-term

this a done While demonstrating so these pleased value in exceptional there of with are have focus well third revenue very in has across syringe position we kicked as dimensions, QX QX I the prefilled with the presentation auto includes high since to This we will $XX quarter of in achieved injector sales share. the increase X franchise #X the UDENYCA each QX million Also is the through customers. this franchise XX% first. Significantly, retained reaching particularly to XXXX revenue our UDENYCA into growth X XXX% its and QX, gear UDENYCA well performance market nearly and franchise working year UDENYCA from XX% that the options; our ONBODY, delivering quarter.

We growth to expect to in UDENYCA XXXX. return market

report to for final address happy and our me supply this week. production of schedule, you manufacturing our to moment. overall Now packaging UDENYCA let UDENYCA and based resuming a the is updated chain interruption contract strategy just the organization that on supply packaging I'm labeling

completed, backlog these they targeted, is an comprises delay. customers next plan as will as X weeks. the making to fashion. they it's note that weeks in or interruption process This without they restarting, our lots While than final UDENYCA expect get to the sure channels expected This be allow completed to distribution are XXX,XXX several restock units worth we us possible representing ship a as of expedited later this now fast supply, lots are over the is previously as about to to few XX product CMO important that which further months' to all

Now model that you QX our dynamics. exercise that in understand do not the to channel with sales have and partners now just will today, we estimate restocking January. a customers started effort and provide is early we to have uptake we and but one how Since the the starting, have impact working schedule, plan QX sales for

planned requisite also are bringing and the qualification Setup made labeling million annually, will to supply Salable We product rest to and successfully are diversify our have been we ongoing. with completed, chain. manufacturing authorized X lots consistent and packaging and from sale, an doubled significant and packaging operation to additional supply of capacity in units and is the labeling lots underway of once online December have for chain. over test start this further expand have our order regulatory progress the discussions in CMO manufacturing is our UDENYCA

ready will and XXXX for in share increases We and be substantial to market growing the demand meet UDENYCA expect beyond.

LOQTORZI I'll on nasopharyngeal quarter-over-quarter sales grew more my our well first XX% commercial call. plan. agent. provide turn execute approved our to continue as Commercial Now launch Paul our Reider, LOQTORZI later to detail we Chief immuno-oncology against will cancer in Officer, and

just LOQTORZI the of in have combination potential foundational of treatment let that long-term we me the for our NPC a and element So say tremendous in therapy strategies. as confidence

opportunities candidates, the excited drug so As our pipeline about why me of innovative let there. share immuno-oncology I'm

responses living response on promising candidates enhancing people focused First, and adaptive innate tumor for a portfolio improve enable immunotherapy with and our immune cancer. microenvironment and includes outcomes robust antibody to differentiated drug the diversified immunological

efficacy of areas for on a that development in Second, most of our types focuses into line opportunities target providing mechanism, combinations substantial strong targeted proof need. established years. have sight types attractive turn in our of and several potential that patient tumor an populations the the addressable across target strategy improving shareholder high will unmet candidates thirdly, market the in drive drug tumor upcoming need large unmet with value And

I CHS-XXX of respectively, XXXX. reporting the II near-term catalysts, Dr. Dias casdozo, forward will Phase and first detail. As trials Lavallee look Theresa Dr. half on Rosh for the speak as let we in and far I to clinical But to and

Lastly, positive cost our that reiterate in financial cover which Officer, to saving and now balance the high will call. Chief this efforts a later on McMichael, disciplined over priority reflected from management Coherus remains at Financial impact our I'd seeing last sheet, Bryan year we are like our the

ability long-term We in our our value pipeline. are to shareholders for our our confident positioned create and competitively very through portfolio both product

are our take over the I'll We goals and the that, to and for can our call executing Paul. with vision excited about well turn moving against where forward. And strategy are us year

Paul Reider

and everyone. Thank you, Denny, good afternoon,

X revenue in was QX steady over fueled net a will follow near the by increase long-term LOQTORZI XXXX. execution QX, revenue and a patient in oncology quarter commercial line on quarter sustained line following acquisition $XX product million by of $XX.X which impressive highlighted $X.X with patients, consecutive fully results XX% quarter and its duration net materialize. million, third progress is quarter-over-quarter commercial million dedicated sixth Our driven LOQTORZI reiterate will of Total revenue top new estimate that revenue We a increase for quarter-over-quarter. in term XX% to by continues to of ramp continuing XXX% belief our LOQTORZI for increase a over we growth UDENYCA as QX X million strong years to a was launch. XX% $XX.X take value revenue deliver was the over early (sic) from growth QX. ], a UDENYCA net time [ increase XX%

million. chemotherapy longest in line of on our that to well at based continue LOQTORZI we on market that X,XXX are early of the project indicating year results X grew will call, LOQTORZI position therapeutic on early acquiring approximately patients with the and population. the near OS $XXX in line and the a the eligible As of achieve to focused our more PFS the I on LOQTORZI time and of and HCP share the launch total optimizing are make NPC market LOQTORZI targeted strong NPC patients remain progress on It's and dominant would and in is we too the majority LOQTORZI top treated population. Based NPC line are the total therapy. Overall, patients that treatment. through patient of evidence, combination making In but delivered patient of remain treatment; real-world benefit. progressing approximately by combination patients term, being conclusions duration messaging have than X/X estimate to patients JUPITER-XX, and priorities driving outlined from to treatment XX% early share number treatment and a duration the started early receive XX% treated be greatest have in who are represent are LOQTORZI new expected QX patients of at early launch identification, are total ensuring QX, In there $XXX duration on impressive strong eligible each in drivers: we the decision the acquiring approximately and chemotherapy the million patients priority. LOQTORZI of Therefore, LOQTORZI line valued still is revenue patient to of

UDENYCA. regarding Now

delivered the growth Our overarching X of by by of I'm strategy report revenue driven to pleased maximize franchise and the quarter and execution is long-term fueled another to for continued UDENYCA drivers. UDENYCA revenue strong

XX% XXXX Despite a of of broad for only quarter-over-quarter interruption, a is in meet more opens to net and of the XX% to the ONBODY; providers demand UDENYCA was lives. better, in significantly unique overall commercial, is Advantage be payer XXXX. UDENYCA driven fee-for-service with XXXX the patients; similar, temporary declining which higher to if we Today, and pegfilgrastim price. by second, X overall ONBODY as due as selling plans launch on coverage, the Medicare commercial UDENYCA well QX to XX% over not franchise third, than options successful different and the anticipate revenue X% delivery First, supply covered needs access in increase brand and coverage increase patient demand

fueled the customer time the X-minute compared prefilled syringe mix its Regarding and UDENYCA in launch the XX% ONBODY for positive. Demand Neulasta Onpro. be to injector remain receptivity SKU X%, represented respectively. for and to the ONBODY, for XX-minute with features accounted such of and injection ONBODY's franchise XX% QX is as continues QX, to-date we In ONBODY differentiated presentations by auto performance very while delivery pleased

UDENYCA position share, #X in its XX% class maintained market market pegfilgrastim Regarding the share. with

to generating that replenishment we set early frame. November the in to and respect Denny us are in plan with the December his Therefore, remarks, the X laid out focused resume time timeline priorities. Now resupply late up to sales on quantity

innovative each UDENYCA demand, First, in with take in QX turn resume and share the to to as that differentiated prescribing which XXXX and is device that, UDENYCA the remains could second, reestablish pillars: working the X in on we broad workflows. That demand looks better to competitive strong which the resume market QX position X a our And UDENYCA predict customers acceleration and it as distribution said, good to sets will the to of XXXX. With with difficult or I'll Theresa pace be customers XXXX patient brand closely replenishing and channel. now Lavallee. options Dr. order payer franchise with throughout the Theresa? account ONBODY to based remain compared call coverage, confident presentation, for brand as time only and

Theresa Lavallee

and Thank you, Paul, good everyone. afternoon,

benefit promise that with the combination of in that to Inhibitors of desert not as the on classified tumor cold patients Now PD-X in PD-X these the In tumor renal cancer; patients. cancer only are are half respond of PD-X development revolutionized targeted minority cancer. such our than and Coherus hot a treatment. of limitation and to pancreatic colorectal types from patients. works inhibitors discuss as immune Moreover, TME that to tumor The bringing as or is such some classified survival do types have and lung, enjoy there toripalimab. long-term inhibitors as focus cancer survival PD-X are treatment care pipeline for long-term bladder many types less

non-small proof sight of posters have a don't mechanisms not lack lung to the CCRX and to response presentation in antitumor the and major cell suppression of casdozokitug of combination activation resulted characterized and the failed indications safety inhibitors. Many the Treg immune have for suppression activity our Conference, strong The proof myeloid-driven cytolytic number in lends or on there but that clinical inhibitors, for on immune and activity, and clinically, particularly will respond is mechanisms data treatment week other concept. encouraging affords targets translation of of has that targeted in of annual in Treg having will next of challenges resistance cell sight agents. showing that cancer tumors promising casdozokitug at targeted and casdozokitug, and concepts. cell line itself cell evaluated subtype are single-agent liver ones monotherapy antagonist focus us squamous PD-X IL-XX cancer the suppression the responses, antibody a activity In these been our to of blocking we line due SITC eliminates the data where tumor. The clinic profile myeloid X been to and have lung preclinical For PD-X with of CHS-XXX, to toxicity of that present

overcome neck patients T to-date second profile selective tumor a continue cancer including high CCRX Chief poster and for targeting and advance prevalence CHS-XXX cytolytic in combination is show of The lymphocytes tumors also and and Optimus now readouts in CHS-XXX previous of toxicity to call safety immune types to clinical clinical now optimization address Treg to colorectal is antitumor will biomarker presented head broad tumor-resident proof of Rosh? solid of neck, key data The or CCRX cells, CCRX our density designed the study Phase FDA's depletion have in alignment the the selectively and cells squamous highest Tregs readouts. The cells, Dias, mechanism. and positive cancers. We in efforts activation turn XXXX expand CHS-XXX, the on Treg to cancer. immune decrease Officer. Dr. CCRX-positive are toripalimab in depletion with also with antibody our leading study cold with with targeting to XXXX. I'll efficacy that prevalence data carcinoma. The depletion with Medical the to SITC is an leading Treg support head of other dose and half autoimmune limitations cells Many positive Advancing Project toripalimab tumors avoiding and of is a in of establishing anticipated ASCO in safety the gastric a Treg with of aim like designed I and pancreatic excellent dose selection and and trials Treg immune activation. cervical nonresponsive cell at

Rosh Dias

portfolio outside in resource Theresa, carcinoma our types you, Perhaps to We strong immuno-oncology pillars, profound continue us LOQTORZI and the develop foundational second to together afternoon, our way its its pipeline tumor importantly strategy indicated our FDA Thank PD-X remains by across X in different strategic and foundational to our an and approval in articulated its NPC with give develop data optimally good survival does line formed additional ability it agent. the development with beyond. previously our to -- line first most as it with demonstrated nasopharyngeal IO advantage the of as in effective key allocation be only combination development everyone. with which for asset further represent of efficient agent NPC, pipeline. and

with the very Firstly, own by tumor assets; types are our our the well us to areas opportunity CCRX targeting beyond combination patient our combination benefit affords internal explore and in indications of in in of immunotherapy. casdozokitug, that our the antibody; first-in-class further with competitively underserved pipeline IL-XX positioned NPC LOQTORZI which antibody the CHS-XXX, cytolytic pipeline

also thirdly, compounds combination combination or Therapeutics close where combination develop LOQTORZI external to which additional where stage partner types Cancer as with Institute combination additional cancer ENB again with Junshi's again with providing such assets in cell tumor cancer. And lung we're the compounds in develop and with partners. with we're Research study discovery external LOQTORZI stage BTLA neck vaccine types LOQTORZI INOVIO with with stage, in the agents head later to to combination ovarian development limited and registration-enabling the at small combination at partner cancer, us discovery which study in stage allows Secondly, tumor early allows in providing combination combination as the such external for study LOQTORZI us later-stage a in the the and with in

the we're whilst our the latter approaches, development of providing partners cost trials. For bear these X development LOQTORZI,

pipeline first our development. me with Let turn starting in each now of internal these take

these Firstly, at communicated with specific encouraging cell data congresses presented casdozokitug. carcinoma. Both and hepatocellular build approaches at previously cancer to data in on indications, We're from X casdozo trials non-small be international further congresses. very upcoming lung sets developing

non-small IL-XX carcinoma subjects in cell, patients arguably shown includes in greater in there's centers key disease also observed in in these both recruiting PD-LX and ongoing activity and with disease, responses partial is is advanced tumors. refractory and where less which We're U.S. responses where inflamed monotherapy has taking cell For were the casdozo-toripalimab trial more medical unmet U.S. densely data a our in in in advanced the forward plan. the to being academic need. casdozo combination present squamous Both with

setting encouraging standard potential tori, the particular to at increase standard XX% a complete benefit. little hinder responses We're ADA congresses. antidrug showing further shown rate multinational atezo bev we in upon data a in of remain a with to U.S. care, with open with and ORR rate a later communicated of data data complete previously bev For bev, combination this the has have in HCC, of care of and follow-up remain of about GI of casdozo as forward we combination the study patient at this overall new and track line the these rate over responses, ASCO existing with responses excited may on atezo an response tori antibody the of year added of relatively the at low with With year. that study this this high current we as building casdozo and communicating first upcoming XX% the from X when start an look year-ago. these X extended to communicated Again, presented a

strong squamous tumor LOQTORZI and primary U.S. the that tori investigating recruit where For plan. type our CHS-XXX, indication, is in continues carcinoma, complementary monotherapy is our to ongoing combination with both and existing a approach disease head trial linkage our to to and is neck cell in

combination with the we're their further a with and in ] in with year patient As on showing study planning from in to presented Tregs gastric head gastric Lenova data at [ to increasing get number with cancer our currently a aiming high planning in we're that a basis to tori prevalence for encouraging and reminder, disease strong biopsy CCRX-positive combination and samples the from pleased open in of this of I'm antibody are indication cancer the ASCO also announce CCRX on toripalimab. expansion neck. linkage paired study further CHS-XXX

potency selectivity open excited form and the combination, next CCRX, our year. of exploring potential cohort our tori the we're With a the which and to with in quarter X own will which study preparing we're CHS-XXX of about tumor of types additional in first

sponsored For approaches, in combination communicated our for head ovarian with as the studies combination ongoing the remain Junshi tori, limited cell. startup study and partnership in in small and with previously investigating with cancer ENB stage or utilizing in BTLA combination in or tori the multinational either alone the Therapeutics Junshi's LOQTORZI both INOVIO neck observation

a with head McMichael, Financial in I'll ongoing Bryan investigation received investigator of sponsored for with Officer. that, over have to our interest Bryan? neck ISTs we physicians Chief toripalimab very much and program from active being the for hand and Finally, cancer beyond. And

Bryan McMichael

you, good Thank afternoon, and Rosh, everyone.

execute our as shared, strategy. we strong it and was Denny As quarter Paul on to continued a successfully

sharpened results. on is Our oncology focus delivering

from for a a lower reflect result expenses were $XX and in year-ago. Savings to expense. of expense interest or expense Third further in investments with quarterly supply through expanding and saw gross pipeline products profit by by headcount. preapproval XX% slightly offset past first coupled a higher expense partially despite XXXX continued commercial Cost SG&A in fully The the from related the onshoring loan margins, million, million, revenues the improved and primarily significant led down interest $XXX The in XXXX the QX QX to for primarily includes $XX to September XXXX. The non-GAAP $XX.X securities I'll stock-based on cash the at due or million sold will to were compared net was million last we compared same R&D half the supply This call decline earnings million expenses was capacity for remarks. revenue of realized per XXXX of R&D XX% operating QX was our range manufacturing. of in expenditures of and of and per reduced as and loss gross net lag partially with $XX.X or lower excludes on decrease X, year. and XX, $X.XX Denny now year. XXXX. decrease the in to products impact million high a both year net are certain significant and from million $XX.X be the approximately totaled temporary during comparable development loan payment divestitures terms chain $X.X derisking customers. on million million reducing the purchase R&D diluted divestiture $X.XX our which the and to The diluted compared QX redundancy share in in turn the year, over $X.X direct from principal impact This equivalents diluted revenue our profit, primarily This million and goods XXXX costs revenue third which of that, QX to Interest compensation $XX.X million, $XXX to Today, QX XX% $X.X quarter commencing gross expense lower in $XX.X improvement in guidance R&D of $XX.X our sale for totaled business XXXX noncore $XX.X of is agreement, our million a offset savings period amount to $X of or activities. With were term expected $XX.X prior pipeline. expenses compared lower COGS decrease of loss in diluted in net year-over-year back XX% million. end paying investments combined inventory or these Cash, million. in $X.X driven share our QX to per quarter to by closing SG&A million only XXXX. $X.XX decrease period reflects XXXX $XXX.X QX $X.XX a candidates per of and year-end. interruption with supply million, or primarily same investments while QX term off XXXX, the May net XXXX for year. share or of was $XX.X million cash million loss million $XXX last or QX marketable will million quarter share the for was

Dennis Lanfear

Bryan. execute team Year-to-date their continue supply deliver as X-part interruption you, want work hard I plan our Thank we thank value, to for issue. manufacturing shareholder on outstanding our progress to and our and on to our for team commercial their results

While now together therapies lot, a happy extend to to and to open bring accomplished innovative patients we there turn do the is cancer as more to questions. line strive survival. I'm Operator? their we have for

Operator

[Operator Kripa Instructions] comes Securities. Our Devarakonda with first Truist from question

Alexander Xenakis

the given as have outlook And what's responses some both seen nonsquamous and Some high-profile well in of performed some would the ADCs seeing from running. the trial actually your quarter. the excited that competition? area see on is chain from some histologies? we've your Congrats of for and a the on Kripa. failures Xenakis to team liked. I the all in We're some Alex have What the are which the on up is in second attention. tori casdo supply have and lung, gotten line expectations for has getting This as people on squamous question

Dennis Lanfear

and Chief Rosh Medical our one I'll add question, then the Officer, for Rosh? let answer Dr. let Thanks for Dias, we'll Alex. Dr. Lavallee it. that to you

Rosh Dias

the question. Thanks, Alex, for

that that previously for cell cancer So upon what building seeing some think lung sets communicated. data I non-small specifically, we we're is nice we're

a partial -- seen have that's who Obviously particularly and have we refractory in We terms demonstrated responses. previously have inflamed subjects rare, in less patients PD-LX of monotherapy also of tumors. that couple and

a have a stage rare that study second overall now we actually The standard is right The taking alone line line is rate. see. is terms of a proceeding care in So encouraged like very response so docetaxel by. measurably we're forwards we pretty in ongoing to low The we're and we're would design with observation in what typically low. that bar that's second of pretty

the docetaxel. to really science out. we study III pan care the go, results we're looking following with we the how to this on versus we'll think I Depending move again and at forward So standard how subsequent plan see combination a Phase of these

Dennis Lanfear

you have additional any do comment? Theresa,

Theresa Lavallee

Yes.

as Just well add we're in broadly -- second were as across responses the as the line. monotherapy lung that subtypes think of third I to looking were that lines the that cancer and therapy, responses

a for has had have combination a who in Surface that study stable pembro with also We on casdozokitug was with the over disease patient year.

is sense. response think mutations. showing to since target common I to is was So tissues such of second to really of IL-XX from adenocarcinoma casdozokitug to a a immune dampen due got a The akin and way smoking became infection more squamous in lung. important it makes as barrier an that standpoint lung the And to a in that response that we signal whereas to that really seen is more limit focusing cancer on the lot was and subset we've from line biology more where infection third incidence really common squamous IL-XX interest as when think the of

of it IL-XX greater expression keen cancer. think of So still for in interest be these subtypes since is to lung later lines way across also in We lung really looking be all activity. the across cancer could earlier high therapy, histology might a enrich

Operator

Our next Yigal from with Citi. comes Nochomovitz question

Ashiq Mubarack

wondering is on My a wanted shelf And see the understanding UDENYCA? the but channel sense was accounts the how impact? when didn't for will Were situation. for you managed the UDENYCA any helpful. Yigal. restocking. Can a on necessarily couple there enough other give commercial on where they can color maybe clarity us the UDENYCA week, products on they some particular using that Ashiq at to is you level products or ask This be production when this will start us feel hospital some have I again? give without would Any be inventory might in available there

Dennis Lanfear

We're you respect Paul? question. hanging the the the And availability supply for on happy some and certainly Paul for us. much so be behind I'll with make interruption comments to let you the customers with us. Thank putting to shelves

Paul Reider

Yes. question. your Thanks for

to So resume in the late sales November, we're time expecting early December frame.

have of demand occur the we'll chain and a robust replenishment through and then time December on time, very XPL late we customers, beginning that the to November in expect over at course the supply then So from product based beyond. anticipated our that in

start into mentioned, reintegrate UDENYCA going resume. We customer expect pace the which to workflows. I we're the demand also of to have to as as watch customers But to

tell However, confidence us conversations were that the who soon have they given number and UDENYCA on I to that the it's will who been based days with customers of resume few interruption you prior prescribing my as as available. assurances we've UDENYCA had the has that bolstered over using supply last can

the start December that into we're and of November, early confidence got market. an giving late going and presentation So think I X year ONBODY things coverage broad payer options differentiated to the with value by demand again sales high and we've be X bolstered by XXXX. to we're fact device, the seeing innovative the the of customers to accelerating are we've that got continues and customers the coming those end back by And

the that supply for that come to prior demand out UDENYCA is there today we there that. was So of as interruption

of very time. confident and out we're bullish coming of this feeling So period

they've some for ways. gone so that a really question. able during to one, we if other to available to upon be they to product resupply. have a or back Number access about be coming and that me that that's either device UDENYCA. able brand. accounts that channel the period have very the Two without good than access had in pegfilgrastim been Now us we're to going if gone innovator needed the But managed back there minimal they're hearing them all them. to product not because entire was an indications would only you time, then mentioned, the they accounts But they to ONBODY product asked how bridge may impact that I were ONBODY to competitive as throughout is It's

Operator

Cowen. from Michael comes question next TD with Our Nedelcovych

Michael Nedelcovych

have a histology trial little casdozo and cancer. in that that detail lung benchmark the is on to give rate a that subgroups a maybe it on you response more perhaps is trial in Could a a early you rate as combo? based docetaxel mind the in late-line follow-up a as kind response decent think and a relates especially target. benchmark especially in maybe in trials for on The have moving the I us docetaxel have of threshold good you mind or you

Dennis Lanfear

want to that? you do Rosh, take

Rosh Dias

the for Michael, Thanks, Yes. question.

what doce in is as typically second say, you around you're or response right, second you overall see, care. standard ] line line. of So XX% is docetaxel remi rate a Typically the [ the

be So increment we this standard deep essentially but stats, will be too Simon the will into looking for a that. won't design. go over an I X-stage

stages. -- So we meet would Michael, to that we at at looking the mark. your in have we're like certain different is to But docetaxel thresholds ORR the that question, base specific the answer XX% baseline around

Operator

HCW. question comes Our Tsao with from Douglas next

Douglas Tsao

curious the demand just marketplace? all I'm the end a be in meet November. follow-up point you'll to so able think you of At on UDENYCA. be at selling just do again you'll guess what I

Dennis Lanfear

question, for Doug. your Thanks

great a that's question. think I

We have X some scheduled units XXX,XXX produced in weeks. be to

prior several the think year So months' and production. I that's that's to end the of

the within X this X, would say I into So weeks, all market. product have we'll maybe

moving it's quickly resupply. So the very on

Douglas Tsao

fourth sort up to customers come to get to sort or time so of had do sort that you'll full first the by by do and So so you'll of impacted, any think of be back take will you contingencies running supply, sort given -- it be the to up will Denny, quarter you so back speak? quarter obviously normal beginning once be fact think the while hopefully of back the you and that with

Dennis Lanfear

be again in little the shake Doug? Well, channels, just your follow-up that I further out for distributors, in how the will particular in from resupplying once January. and thoughts certainly occurring But about a comment there I'll any question let going QX. Paul think forward things December into on Paul,

Paul Reider

Yes. for Thanks Doug. question, your

UDENYCA, practices start demand return the to ultimately each quarters each if to the the as to to behalf. whether going how reverify had have they've supply which or So during a other they're which upon interruption, not got decision therapy make they're that requires some to decisions words, acceleration the switch prior to they're patient treat going a operational patient. insurance another of of on to going dependent to make patient and the be some to They on account's the will I will pace it different In requires on think work. that burden

I means think of their faster. intention that demand to acceleration do be the some returning pace accounts which have signaled will that,

the starts. new accounts getting just them and to that then all not let and treatment patient's we'll other disrupt going there's run be are think patient I

be importantly, or So to Most get going that TSI. demand want the easy greater our that ensure I levels smooth prior had the monitoring. to dynamics very are to think and we with each at even to we be just we can account that a so transition those we're

Dennis Lanfear

QX very driven existed think QX. was it's coverage. Paul conditions interruption a including presentations of our supply mind I increase keep our quarters of in that before out, consecutive over recovery Doug, our to and this the demonstrated as drive important by they X market X XX% well-differentiated after to interruption. ONBODY And UDENYCA the the strong from largely growth and supply share device, our will Those pointed

trajectory in but So predict on bullish the back indicated, acceleration, coming fairly us. customers as Hard to are that. we're these Paul to exact

Douglas Tsao

have diversify they're the that in And chain of customers disruption? supply that any volume their they less had indicated to have going purchase just as you because

Dennis Lanfear

No.

Operator

from with comes Brian Our question Cheng next Instructions] [Operator JPMorgan.

Lut Ming Cheng

UDENYCA you even to quick formulations restocking, across or a expect of I follow-up. priority over given have versa? syringe ONBODY On And is prefill or your X restocking do an vice there

Dennis Lanfear

to that want take one? Paul, do you

Paul Reider

follow going in for Brian. then ONBODY we're thing. of Yes, your restocking to come by question, first Sure is to followed a kind auto-injector. sequential flow. prefilled syringe, going Thanks

So it each working and the that we'll of account ordering be with now each of course will for in come their SKU, respectively. order on

will continually then prior. as in follow we the then Once will state past will initial, get just the everything It will the steady occur sequentially. and resupplied it it be be channel. So

Lut Ming Cheng

then helpful. That's may maybe other they to plan And who Do shortage. over have have other Okay. and had during very the contingency purchase from reimburse that to just discussed one given that you patients treatments more to suppliers? you your to switch on

Paul Reider

no. Generally,

Operator

I This closing for the like now session. it turn question-and-answer Denny to would back Lanfear you. concludes to remarks. Thank

Dennis Lanfear

all Thank our call. you for us very joining much, you today Daniel, and thank on

updated continue other we in on to QX. make interruption very franchise with QX. microenvironment see, UDENYCA lastly, at can And in you our will the tumor we you Thank so on. pipeline, to of our see progress continuing SITC side all keep [ good Daniel. progress our we'll As We And ]. that look agents the you, on IO you and forward supply on

Operator

This call. Thank concludes today's conference you participating. for

You disconnect. may now

Coherus BioSciences (CHRS) 6 Nov 242024 Q3 Earnings call transcript